Diagnostic MicroRNA Signatures to Support Classification of Pulmonary Hypertension
Circulation: Genomic and Precision Medicine · 2025
DOI: 10.1161/circgen.124.004862 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Circulation: Genomic and Precision Medicine, 2025. Verfasst von Niamh Errington und 18 weiteren Autor:innen. Beteiligte Einrichtung: National Heart and Lung Institute, Imperial College London, United Kingdom (N.E., C.J.R., J.W., L.S.H., D.W., M.R.W., A.L.). Hauptthemen laut MEDLINE: Hypertension, Pulmonary, MicroRNAs. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
BACKGROUND: Patients with pulmonary hypertension (PH) are classified based on disease pathogenesis and hemodynamic drivers. Classification informs treatment. The heart failure biomarker NT-proBNP (N-terminal pro-B-type natriuretic peptide) is used to help inform risk but is not specific to PH or sub-classification groups. There are currently no other biomarkers in clinical use to help guide diagnosis or risk. METHODS: We profiled a retrospective cohort of 1150 patients from 3 expert centers with PH and 334 non-PH symptomatic controls (disease controls) from the United Kingdom to measure circulating levels of 650 microRNAs (miRNAs) in serum. NT-proBNP (ELISA) and 326 well-detected miRNAs (polymerase chain reaction) were prioritized by feature selection using multiple machine learning models. From the selected miRNAs, generalized linear models were used to describe miRNA signatures to differentiate PH and pulmonary arterial hypertension from the disease controls, and pulmonary arterial hypertension, PH due to left heart disease, PH due to lung disease, and chronic thromboembolic pulmonary hypertension from other forms of PH. These signatures were validated on a UK test cohort and independently validated in the prospective CIPHER study (A Prospective, Multicenter, Noninterventional Study for the Identification of Biomarker Signatures for the Early Detection of Pulmonary Hypertension) comprising 349 patients with PH and 93 disease controls. RESULTS: NT-proBNP achieved a balanced accuracy of 0.74 and 0.75 at identifying PH and pulmonary arterial hypertension from disease controls with a threshold of 254 and 362 pg/mL, respectively but was unable to sub-categorize PH subgroups. In the UK cohort, miRNA signatures performed similarly to NT-proBNP in distinguishing PH (area under the curve of 0.7 versus 0.78), and pulmonary arterial hypertension (area under the curve of 0.73 versus 0.79) from disease controls. MicroRNA signatures outperformed NT-proBNP in distinguishing PH classification groups. External testing in the CIPHER cohort demonstrated that miRNA signatures, in conjunction with NT-proBNP, age, and sex, performed better than either NT-proBNP or miRNAs alone in sub-classifying PH. CONCLUSIONS: We suggest a threshold for NT-proBNP to identify patients with a high probability of PH, and the subsequent use of circulating miRNA signatures to help differentiate PH subgroups.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Heart and Lung Institute, Imperial College London, United Kingdom (N.E., C.J.R., J.W., L.S.H., D.W., M.R.W., A.L.).
- MiRXES Lab, Singapore, Republic of Singapore (Li Zhou, Lihan Zhou, C.H.).
- Janssen Pharmaceutical Companies of Johnson & Johnson, Raritan, NJ (Y.-L.F., T.J.).
- Bioinformatics Institute, Agency for Science, Technology and Research (A*STAR), Singapore, Republic of Singapore (S.K., D.W.).
- Brigham and Women's Hospital and Harvard Medical School, Boston, MA (E.H., A.W.).
- Division of Clinical Medicine, The University of Sheffield, United Kingdom (A.A.R.T., R.C., D.G.K.).
ORCID-Profile: Niamh Errington, Li Zhou, Christopher J Rhodes, Yiu-Lian Fong, Lihan Zhou, Aaron Waxman, John Wharton, A A Roger Thompson, David G Kiely, Luke S Howard, Mark Toshner, Cheng He, Dennis Wang, Martin R Wilkins, Allan Lawrie
Zitieren
APA
Errington, N., Zhou, L., Rhodes, C. J., Fong, Y. L., Zhou, L., Kariotis, S., Harder, E., Waxman, A., Jatkoe, T., Wharton, J., Thompson, A. A. R., Condliffe, R. A., Kiely, D. G., Howard, L. S., Toshner, M., He, C., Wang, D., Wilkins, M. R., & Lawrie, A. (2025). Diagnostic MicroRNA Signatures to Support Classification of Pulmonary Hypertension. Circulation: Genomic and Precision Medicine. https://doi.org/10.1161/circgen.124.004862
Vancouver
Errington N, Zhou L, Rhodes CJ, Fong YL, Zhou L, Kariotis S, et al. Diagnostic MicroRNA Signatures to Support Classification of Pulmonary Hypertension. Circulation: Genomic and Precision Medicine. 2025. doi:10.1161/circgen.124.004862
BibTeX
@article{Errington2025,
author = {Errington, Niamh and Zhou, Li and Rhodes, Christopher J and Fong, Yiu-Lian and Zhou, Lihan and Kariotis, Sokratis and Harder, Eileen and Waxman, Aaron and Jatkoe, Timothy and Wharton, John and Thompson, A A Roger and Condliffe, Robin A and Kiely, David G and Howard, Luke S and Toshner, Mark and He, Cheng and Wang, Dennis and Wilkins, Martin R and Lawrie, Allan},
title = {Diagnostic MicroRNA Signatures to Support Classification of Pulmonary Hypertension},
journal = {Circulation: Genomic and Precision Medicine},
year = {2025},
doi = {10.1161/circgen.124.004862}
}
EUVIMED